The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)

ATM inhibitors, such as 7, have demonstrated the antitumor potential of ATM inhibition when combined with DNA double-strand break-inducing agents in mouse xenograft models. However, the properties of 7 result in a relatively high predicted clinically efficacious dose. In an attempt to minimize attri...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of medicinal chemistry Ročník 61; číslo 9; s. 3823 - 3841
Hlavní autoři: Pike, Kurt G., Barlaam, Bernard, Cadogan, Elaine, Campbell, Andrew, Chen, Yingxue, Colclough, Nicola, Davies, Nichola L., de-Almeida, Camila, Degorce, Sebastien L., Didelot, Myriam, Dishington, Allan, Ducray, Richard, Durant, Stephen T., Hassall, Lorraine A., Holmes, Jane, Hughes, Gareth D., MacFaul, Philip A., Mulholland, Keith R., McGuire, Thomas M., Ouvry, Gilles, Pass, Martin, Robb, Graeme, Stratton, Natalie, Wang, Zhenhua, Wilson, Joanne, Zhai, Baochang, Zhao, Kang, Al-Huniti, Nidal
Médium: Journal Article
Jazyk:angličtina
Vydáno: WASHINGTON Amer Chemical Soc 10.05.2018
Témata:
Chemistry, Medicinal
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Science & Technology
FREE-WILSON
DESIGN
STRAND BREAK REPAIR
LIPOPHILIC EFFICIENCY
DNA-DAMAGE RESPONSE
PROTEIN-KINASE
IN-VIVO
HISTONE H2AX
ABSORPTION
CANCER
ISSN:0022-2623, 1520-4804
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:ATM inhibitors, such as 7, have demonstrated the antitumor potential of ATM inhibition when combined with DNA double-strand break-inducing agents in mouse xenograft models. However, the properties of 7 result in a relatively high predicted clinically efficacious dose. In an attempt to minimize attrition during clinical development, we sought to identify ATM inhibitors with a low predicted clinical dose (<50 mg) and focused on strategies to increase both ATM potency and predicted human pharmacokinetic half-life (predominantly through the increase of volume of distribution). These efforts resulted in the discovery of 64 (AZD0156), an exceptionally potent and selective inhibitor of ATM based on an imidazo[4,5-c]quinolin-2-one core. 64 has good preclinical phamacokinetics, a low predicted clinical dose, and a high maximum absorbable dose. 64 has been shown to potentiate the efficacy of the approved drugs irinotecan and olaparib in disease relevant mouse models and is currently undergoing clinical evaluation with these agents.
ISSN:0022-2623
1520-4804
DOI:10.1021/acs.jmedchem.7b01896